We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Sage Bionetworks Announces Oncology Research Partnership with Pfizer
News

Sage Bionetworks Announces Oncology Research Partnership with Pfizer

Sage Bionetworks Announces Oncology Research Partnership with Pfizer
News

Sage Bionetworks Announces Oncology Research Partnership with Pfizer

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Sage Bionetworks Announces Oncology Research Partnership with Pfizer"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Sage Bionetworks has announced a new research partnership with Pfizer, Inc. to build, analyze and exploit advanced network models of cancer.

Pfizer will provide research funding to Sage to analyze large, globally coherent datasets from Pfizer, Sage and the public domain. Through innovative network biology analysis Sage will use the genetic, molecular and clinical information to create predictive computational disease models. These models will help identify therapeutic targets for oncology drug development as well as aid in evaluating the efficacy and safety of drug development candidates.

“We continue to implement our partnering strategy as part of our larger mission to build a Commons where users can exploit the full potential of network analysis across multiple complex datasets.”

“Our collaboration with Pfizer will help develop more innovative and more effective disease models and in turn help define specific patient sub-populations most likely to respond to new therapies,” said Dr. Stephen Friend, President of Sage Bionetworks.

“We continue to implement our partnering strategy as part of our larger mission to build a Commons where users can exploit the full potential of network analysis across multiple complex datasets,” Dr. Friend added. “Data and models from the collaboration will become available in the Sage repository one year following the completion of the project expanding the datasets publicly available.”
Advertisement